Figure 2.

LNGFR ⁺ EMSCs have a greater osteogenic capacity than LNGFR ⁻ EMSCs. (A‐G) LNGFR ⁺ and LNGFR ⁻ EMSCs were treated with osteogenic induction medium for (A‐E) 7 days or (F and G) 21 days. On day 0 and day 7, the (A, B) mRNA and (C) protein levels of ALP and RunX2 were detected by qPCR and Western blot, respectively, using GAPDH as a control. (D) On day 7, the ALP staining depth was observed by optical microscopy (Scale bar = 50 μm). (E) The ratio of ALP activity from the triplicate assays were analysed with Imaging‐Q software, and the representative result was shown in (D). (F) On day 21, the mineralized nodules were photographed after Alizarin red staining (ARS staining) (Scale bar = 150 μm). (G) The results of alizarin red staining from the triplicate assays were analysed with Imaging‐Q software, and the representative result was shown in (F). *P < .05